Abstract
Methotrexate (MTX), used as a graft-versus-host disease (GvHD) prophylactic agent in hematopoietic stem cell transplantation (HSCT), exerts its effect via folate cycle inhibition. A critical enzyme involved in folate metabolism is 5,10-methylenetetrahydrofolate reductase (MTHFR). We examined the association of a single nucleotide polymorphism (SNP) at position 677 in the MTHFR gene on GvHD outcomes in allogeneic HSCT patients administered MTX. MTHFR genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) on 193 HSCT patients and donors. A total of 140 patients were transplanted with an HLA-matched related donor and 53 with an unrelated donor. GvHD outcomes were compared between genotypes by univariate and multivariate analysis. The combined donor 677CT and TT genotypes were associated with a decreased incidence of GvHD (acute and chronic combined) in HSCT recipients with an HLA-matched related donor (75% at 1 year in the CT and TT group compared with 91% in the wild type CC group, P=0.01), increased time to onset of first GvHD (P=0.001) and time to first GvHD treated with systemic therapy (P=0.022). Unrelated donor MTHFR genotype was not associated with outcome parameters and no associations of recipient genotype in either related or unrelated donor cohorts were observed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP . Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated T cells. J Clin Invest 1998; 102: 322–328.
Fridland A . Effect of methotrexate on deoxyribonucleotide pools and DNA synthesis in human lymphocyte cells. Cancer Res 1974; 34: 1883–1888.
Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99: 5606–5611.
Budzik GP, Colletti LM, Faltynek CR . Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line. Life Sci 2000; 66: 2297–2307.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common polymorphism in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113.
Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML et al. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999; 6: 359–365.
van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044–1051.
Robien K, Ulrich CM . 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571–582.
Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231–234.
Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM . Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268–1275.
Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004; 63: 1227–1231.
Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B et al. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 2004; 10: 7592–7598.
Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13: 1915–1918.
Pavarino-Bertelli EC, Sanches de Alvarenga MP, Goloni-Bertollo EM, Baptista MA, Haddad R, Hoerh NF et al. Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients. Transplant Proc 2004; 36: 2979–2981.
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.
Lee SJ . Chronic graft versus host disease. In: Atkinson K (ed). Clinical Bone Marrow and Stem Cell Transplantation, 3rd edn. Cambridge University Press: Cambridge, 2004, pp 1133–1143.
Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E . Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391–2398.
Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N . Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11: 593–600.
Quinlivan EP, Davis SR, Shelnutt KP, Henderson GN, Ghandour H, Shane B et al. Methylenetetrahydrofolate Reductase 677C → T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynucleosides. J Nutr 2005; 135: 389–396.
Kimura M, Umegaki K, Higuchi M, Thomas P, Fenech M . Methylenetetrahydrofolate reductase C677T polymorphism, folic acid and riboflavin are important determinants of genome stability in cultured human lymphocytes. J Nutr 2004; 134: 48–56.
Hryniuk WM . Purineless death as a link between growth rate and cytotoxicity by methotrexate. Cancer Res 1972; 32: 1506–1511.
Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F et al. Effect of methylenetetrahydrofolate reductase 677C → T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103: 294–299.
Dawson H, Collins G, Pyle R, Deep-Dixit V, Taub DD . The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev 2004; 125: 107–110.
Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78: 911–918.
Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281–285.
Varney MD, Lester S, McCluskey J, Gao X, Tait BD . Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Hum Immunol 1999; 60: 532–538.
Acknowledgements
This study was supported by a Research Grant from the Australian Red Cross Blood Service Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murphy, N., Diviney, M., Szer, J. et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 37, 773–779 (2006). https://doi.org/10.1038/sj.bmt.1705319
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705319
Keywords
This article is cited by
-
Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation
Bone Marrow Transplantation (2018)
-
Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD
Bone Marrow Transplantation (2015)
-
Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study
Blood Cancer Journal (2015)
-
Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT
Bone Marrow Transplantation (2013)
-
The role of non-HLA gene polymorphisms in graft-versus-host disease
International Journal of Hematology (2013)